Anti-neutrophil antibodies (anti-MPO-ANCAs) are associated with poor prognosis in breast cancer patients

p-ANCA acting as a proinflammatory molecule. In 1, autoantibodies produced against myeloperoxidase inside the tumor microenvironment promotes immunemodulation of dendritic cells, consequently inhibiting lymphocytes activation. The proinflammatory environment maintained by tumor associated neutrophil...

Full description

Saved in:

Bibliographic Details
Published in:	Immunobiology (1979) Vol. 225; no. 6; p. 152011
Main Authors:	Scandolara, Thalita Basso, da Silva, Janaína Carla, Malanowski, Jéssica, de Oliveira, Janoário Athanázio, Rech, Daniel, Panis, Carolina
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier GmbH 01-11-2020
Subjects:	Anti-MPO-ANCAs Antineutrophil antibodies Breast cancer Myeloperoxidase Prognosis Anti-MPO-ANCAs Myeloperoxidase Antineutrophil antibodies Breast cancer Prognosis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	p-ANCA acting as a proinflammatory molecule. In 1, autoantibodies produced against myeloperoxidase inside the tumor microenvironment promotes immunemodulation of dendritic cells, consequently inhibiting lymphocytes activation. The proinflammatory environment maintained by tumor associated neutrophils undergoing netosis favours the immunosurveillance of tumor cells and its metastatization, as shown in 2 and 3. This mechanism seems to occurs mainly in poor prognosis tumors such as high histological grade, triple negative phenotype and younger and overweight women. [Display omitted] Anti-neutrophil antibodies are capable of activating neutrophils in sterile environments, releasing extracellular traps containing myeloperoxidase (MPO) and anti-MPO antibodies (MPO-ANCAs or anti-MPO-ANCAs), which have been implicated in the pathogenesis of several diseases. The present study evaluated systemic and tumor tissue levels of anti-MPO-ANCAs breast cancer patients, and its relation to clinicopathological characteristics. Anti-MPO-ANCAs were measured in serum and tissue samples of 150 patients by enzyme-linked immunoassay. Samples were pooled according to clinicopathological characteristics of patients. Higher anti-MPO-ANCAs levels were detected in groups presenting negative clinicopathological characteristics, such as high histological grade tumors and risk factors such as body mass index, menopausal status and early onset at diagnosis. The present data highlights anti-MPO-ANCAs as associated to poor prognosis in breast cancer, a role beyond its actually discussed role in autoimmunity and vasculitis.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0171-2985 1878-3279
DOI:	10.1016/j.imbio.2020.152011